Patients’ Features
| Patient . | Age (mo)/ Sex . | Diagnosis . | Conditioning . | GVHD Prophylaxis . | Acute GVHD . | Acute GVHD Treatment . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|
| GRMA | 12/M | AR-SCID T−B+ | BuCy | CsA (7 mo) | I | PDN, ATG | A +50-150 |
| MOGI | 8/M | Omenn’s syndrome | BuCy, VP16 | CsA (9 mo), ATG | II | PDN | A +68 |
| RICR | 10/F | Omenn’s sydnrome | BuCy | CsA (5 mo) | I | PDN, ATG | A +48 |
| SAAL | 1/M | XL-SCID T−B+ | ATG | CsA (7 mo), MTX | 0 | None | A +60-150 |
| SPCH | 48/F | CID | BuCy, thiotepa | CsA (6 mo) | I | PDN, ATG | A +29 |
| SURO | 34/F | HLA II deficiency | BuCy | CsA, MTX, ATG | IV | PDN | D +4 |
| VAMI | 7/M | XL-SCID T−B+ | BuCy | CsA (12 mo) | III | PDN | A +41 |
| TEDA | 7/M | SCID T−B− | BuCy | CsA (7 mo) | I (skin) | PDN | A +29 |
| Patient . | Age (mo)/ Sex . | Diagnosis . | Conditioning . | GVHD Prophylaxis . | Acute GVHD . | Acute GVHD Treatment . | Follow-up (mo) . |
|---|---|---|---|---|---|---|---|
| GRMA | 12/M | AR-SCID T−B+ | BuCy | CsA (7 mo) | I | PDN, ATG | A +50-150 |
| MOGI | 8/M | Omenn’s syndrome | BuCy, VP16 | CsA (9 mo), ATG | II | PDN | A +68 |
| RICR | 10/F | Omenn’s sydnrome | BuCy | CsA (5 mo) | I | PDN, ATG | A +48 |
| SAAL | 1/M | XL-SCID T−B+ | ATG | CsA (7 mo), MTX | 0 | None | A +60-150 |
| SPCH | 48/F | CID | BuCy, thiotepa | CsA (6 mo) | I | PDN, ATG | A +29 |
| SURO | 34/F | HLA II deficiency | BuCy | CsA, MTX, ATG | IV | PDN | D +4 |
| VAMI | 7/M | XL-SCID T−B+ | BuCy | CsA (12 mo) | III | PDN | A +41 |
| TEDA | 7/M | SCID T−B− | BuCy | CsA (7 mo) | I (skin) | PDN | A +29 |
Abbreviations: AR, autosomal recessive; XL, X-linked A; BuCy, busulphan + cyclophosphamide; ATG, antithymocyte globulin; CsA, cyclosporine A; MTX, methotrexate; PDN, methylprednisolone; A, alive; D, dead.
Still receiving intravenous Ig.